Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.

Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H.

Trends Neurosci. 2011 Aug;34(8):430-42. doi: 10.1016/j.tins.2011.05.005. Epub 2011 Jun 21.

2.

Structural imaging in early pre-states of dementia.

Smith CD.

Biochim Biophys Acta. 2012 Mar;1822(3):317-24. doi: 10.1016/j.bbadis.2011.07.002. Epub 2011 Jul 14. Review.

3.

Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.

Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W.

Rev Bras Psiquiatr. 2013 Jul-Sep;35(3):284-94. doi: 10.1590/1516-4446-2012-3505. Review.

4.

Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.

J Alzheimers Dis. 2012;29(2):319-27. doi: 10.3233/JAD-2011-111694.

PMID:
22233766
5.

Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Morris JC.

Arch Neurol. 2012 Jun;69(6):700-8. doi: 10.1001/archneurol.2011.3152.

6.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
7.

Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.

Risacher SL, Saykin AJ.

Annu Rev Clin Psychol. 2013;9:621-48. doi: 10.1146/annurev-clinpsy-050212-185535. Epub 2013 Jan 7. Review.

9.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.).; Alzheimer Association..

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
10.

Advances in the early detection of Alzheimer's disease.

Nestor PJ, Scheltens P, Hodges JR.

Nat Med. 2004 Jul;10 Suppl:S34-41. Review.

PMID:
15298007
11.

[Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].

Verhey FR, Visser PJ.

Ned Tijdschr Geneeskd. 2013;157(11):A5596. Review. Dutch.

PMID:
23484512
12.

Thickness network features for prognostic applications in dementia.

Raamana PR, Weiner MW, Wang L, Beg MF; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2015 Jan;36 Suppl 1:S91-S102. doi: 10.1016/j.neurobiolaging.2014.05.040. Epub 2014 Sep 6.

PMID:
25444603
13.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative..

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

14.

Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease.

Ikram MK, Cheung CY, Wong TY, Chen CP.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):917-22. doi: 10.1136/jnnp-2011-301628. Epub 2012 Jun 25. Review.

PMID:
22733082
15.

Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing.

Belleville S, Fouquet C, Duchesne S, Collins DL, Hudon C.

J Alzheimers Dis. 2014;42 Suppl 4:S375-82. doi: 10.3233/JAD-141470. Review.

PMID:
25190629
16.

CSF and brain structural imaging markers of the Alzheimer's pathological cascade.

Yang X, Tan MZ, Qiu A.

PLoS One. 2012;7(12):e47406. doi: 10.1371/journal.pone.0047406. Epub 2012 Dec 19.

17.

A critical discussion of the role of neuroimaging in mild cognitive impairment.

Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO.

Acta Neurol Scand Suppl. 2003;179:52-76. Review. Erratum in: Acta Neurol Scand Suppl. 2003 Jul;108(1):68.

PMID:
12603252
18.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
19.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

20.

New clinical criteria for the Alzheimer's disease spectrum.

Petersen RC.

Minn Med. 2012 Jan;95(1):42-5.

PMID:
22355912

Supplemental Content

Support Center